M
Mimi Stokke Opdal
Researcher at Oslo University Hospital
Publications - 23
Citations - 367
Mimi Stokke Opdal is an academic researcher from Oslo University Hospital. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 9, co-authored 18 publications receiving 309 citations. Previous affiliations of Mimi Stokke Opdal include Norwegian Institute of Public Health & University of Oslo.
Papers
More filters
Journal ArticleDOI
Simultaneous determination of 6 beta-blockers, 3 calcium-channel antagonists, 4 angiotensin-II antagonists and 1 antiarrhytmic drug in post-mortem whole blood by automated solid phase extraction and liquid chromatography mass spectrometry: Method development and robustness testing by experimental design
Lena Kristoffersen,Elisabeth Leere Øiestad,Mimi Stokke Opdal,Mette Krogh,Elsa Lundanes,Asbjørg S. Christophersen +5 more
TL;DR: The method is used for determination of cardiovascular drugs in post-mortem whole blood samples from forensic autopsy cases and robustness tested by systematically searching for satisfactory conditions using experimental designs including factorial and response surface designs.
Journal ArticleDOI
Determination of Digoxin and Digitoxin in Whole Blood
Elisabeth Leere Øiestad,Unni Johansen,Mimi Stokke Opdal,Stein Bergan,Asbjørg S. Christophersen +4 more
TL;DR: A liquid chromatography-tandem mass spectrometry method has been developed and validated for the determination of digoxin and digitoxin in whole blood samples in autopsy cases and good qualitative correlation with previous findings was achieved for 38 autopsy cases.
Journal ArticleDOI
Genetic Variation of VKORC1 and CYP4F2 Genes Related to Warfarin Maintenance Dose in Patients with Myocardial Infarction
Marianne K. Kringen,Kari Bente Foss Haug,Runa M. Grimholt,Camilla Stormo,Sigrid Narum,Mimi Stokke Opdal,Jan Toralf Fosen,Armin P. Piehler,Per Wiik Johansen,Ingebjørg Seljeflot,Jens P. Berg,Odd Brørs +11 more
TL;DR: In patients with myocardial infarction, the individual contribution to warfarin dose requirements from VKORC1*3, VKORc1*4, and CYP4F2 (1347 C > T) polymorphisms was negligible.
Journal ArticleDOI
Blood GHB concentrations and results of medical examinations in 25 car drivers in Norway.
TL;DR: Most drivers had clinical impairment that was not explainable by injuries, with depressive effects on the central nervous system and sympathomimetic effects on eyes, which concluded that the GHB-drivers most probably drove in an unsafe manner due to impairment by GHB.
Journal ArticleDOI
Therapeutic Drug Monitoring of Clobazam and Its Metabolite-Impact of Age and Comedication on Pharmacokinetic Variability.
Margrete Larsen Burns,Arton Baftiu,Mimi Stokke Opdal,Svein I. Johannessen,Cecilie Johannessen Landmark +4 more
TL;DR: The pharmacokinetic variability of CLB and its metabolite NCLB in clinical practice is extensive, and is influenced by drug–drug interactions, age, and pharmacogenetics, therefore valuable in patient management.